glp 1 atherosclerosis Suppressive effects of GLP-1 on atherosclerotic lesion development in Frontiers | GLP-1 Receptor Agonists

The Amylin Corporation's response to this putative link has been to suggest that it was a consequence of guilt by association rather than a drug effect since pancreatitis is more common in individuals with obesity and type 2 diabetes (15)

[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Doni K, Bhn S, Weise A, et al

Zepbound is a dual GIP and GLP-1 receptor agonist, which means it activates both incretin pathways to enhance blood sugar control and support effective, long-term weight loss

It can also confer kidney-protective benefits and slow the progression of kidney disease in those with type 2 diabetes, a welcome benefit as kidney disease is a common complication of the condition

[Google Scholar] 369.Berenbaum F, et al

[48] Connolly, H